Tianxiao Xu

848 total citations
29 papers, 506 citations indexed

About

Tianxiao Xu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Tianxiao Xu has authored 29 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 20 papers in Oncology and 4 papers in Immunology. Recurrent topics in Tianxiao Xu's work include Melanoma and MAPK Pathways (14 papers), Cutaneous Melanoma Detection and Management (14 papers) and CAR-T cell therapy research (5 papers). Tianxiao Xu is often cited by papers focused on Melanoma and MAPK Pathways (14 papers), Cutaneous Melanoma Detection and Management (14 papers) and CAR-T cell therapy research (5 papers). Tianxiao Xu collaborates with scholars based in China, Ethiopia and United States. Tianxiao Xu's co-authors include Zhihong Chi, Jie Dai, Chuanliang Cui, Lu Si, Xinan Sheng, Jun Guo, Junya Yan, Huan Yu, Yan Kong and Xiaowen Wu and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Investigative Dermatology and European Journal of Cancer.

In The Last Decade

Tianxiao Xu

29 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tianxiao Xu China	14	294	255	110	107	68	29	506
Anxo Martínez-Ordóñez Spain	10	180 0.6×	193 0.8×	144 1.3×	111 1.0×	50 0.7×	15	434
Katriana Nugent United States	8	297 1.0×	202 0.8×	95 0.9×	109 1.0×	61 0.9×	14	460
Junya Yan China	11	241 0.8×	234 0.9×	97 0.9×	94 0.9×	48 0.7×	29	428
Katheryn Begg United Kingdom	4	281 1.0×	163 0.6×	164 1.5×	60 0.6×	82 1.2×	7	505
Hanlin Mok United States	5	292 1.0×	187 0.7×	70 0.6×	90 0.8×	103 1.5×	7	462
Longwen Xu China	10	185 0.6×	172 0.7×	94 0.9×	81 0.8×	61 0.9×	24	361
Dilu Feng China	14	370 1.3×	180 0.7×	219 2.0×	99 0.9×	80 1.2×	26	649
Yuanlin Wu China	11	281 1.0×	118 0.5×	181 1.6×	97 0.9×	77 1.1×	24	469
Emily Capone Italy	16	352 1.2×	396 1.6×	105 1.0×	143 1.3×	95 1.4×	36	723
Eric H.‐B. Huang United States	12	341 1.2×	192 0.8×	67 0.6×	124 1.2×	96 1.4×	15	528

Countries citing papers authored by Tianxiao Xu

Since Specialization

Citations

This map shows the geographic impact of Tianxiao Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tianxiao Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tianxiao Xu more than expected).

Fields of papers citing papers by Tianxiao Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tianxiao Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tianxiao Xu. The network helps show where Tianxiao Xu may publish in the future.

Co-authorship network of co-authors of Tianxiao Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Tianxiao Xu. A scholar is included among the top collaborators of Tianxiao Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tianxiao Xu. Tianxiao Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dai, Jie, Tianxiao Xu, Lifeng Li, et al.. (2025). Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis. Clinical and Translational Medicine. 15(1). e70169–e70169. 1 indexed citations

Wang, Zhiqing, Jiayue Huang, Chunming Li, et al.. (2025). Comparison of angiographically derived coronary radial wall strain and superficial wall stress for the characterization of plaque vulnerability. Cardiology Journal. 32(6). 535–545. 1 indexed citations

Xu, Tianxiao, Wei Yu, Daixin Ding, et al.. (2023). Diagnostic Performance of Intracoronary Optical Coherence Tomography-Modulated Quantitative Flow Ratio for Assessing Coronary Stenosis. Journal of the Society for Cardiovascular Angiography & Interventions. 2(5). 101043–101043. 3 indexed citations

Xu, Tianxiao, et al.. (2023). Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate. Cancer Immunology Immunotherapy. 72(11). 3491–3505. 3 indexed citations

Xu, Tianxiao, Jie Dai, Lu Si, et al.. (2021). EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma. Journal of Investigative Dermatology. 142(4). 1158–1170.e8. 26 indexed citations

Huang, Jiayue, Fan Yang, Juan Luis Gutiérrez‐Chico, et al.. (2021). Optical Coherence Tomography-Derived Changes in Plaque Structural Stress Over the Cardiac Cycle: A New Method for Plaque Biomechanical Assessment. Frontiers in Cardiovascular Medicine. 8. 715995–715995. 12 indexed citations

Dai, Jie, Lu Yang, Tianxiao Xu, et al.. (2020). A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma. Journal of Cancer. 11(10). 2945–2956. 10 indexed citations

Yu, Jiayi, Xiaowen Wu, Junya Yan, et al.. (2019). Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. Journal of Cancer. 10(2). 488–493. 7 indexed citations

Yu, Sifan, Jie Dai, Meng Ma, et al.. (2019). RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma. Cell Death and Disease. 10(4). 254–254. 43 indexed citations

10.

Xu, Tianxiao, Sifan Yu, Meng Ma, et al.. (2018). cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients. Translational Cancer Research. 7(2). 248–256. 1 indexed citations

11.

Yan, Junya, Xiaowen Wu, Jiayi Yu, et al.. (2018). Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics. Melanoma Research. 28(6). 527–535. 3 indexed citations

12.

Xu, Tianxiao, Meng Ma, Jie Dai, et al.. (2018). Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma. Human Pathology. 75. 137–145. 8 indexed citations

13.

Yu, Sifan, Tianxiao Xu, Jie Dai, et al.. (2018). <em>TERT </em>copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma. OncoTargets and Therapy. Volume 11. 4097–4104. 14 indexed citations

14.

Yu, Jiayi, Xiaowen Wu, Junya Yan, et al.. (2018). Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. Journal of Hematology & Oncology. 11(1). 1–1. 140 indexed citations

15.

Yan, Junya, Longwen Xu, Jiayi Yu, et al.. (2018). Prognostic role of NRAS isoforms in Chinese melanoma patients. Melanoma Research. 29(3). 263–269. 4 indexed citations

16.

Yan, Junya, Xiaowen Wu, Jiayi Yu, et al.. (2017). Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. European Journal of Cancer. 89. 90–101. 17 indexed citations

17.

Ma, Meng, Jie Dai, Tianxiao Xu, et al.. (2017). Analysis of TSC1 mutation spectrum in mucosal melanoma. Journal of Cancer Research and Clinical Oncology. 144(2). 257–267. 13 indexed citations

18.

Wu, Xiaowen, Junya Yan, Jie Dai, et al.. (2017). Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. Oncology Letters. 14(3). 3601–3605. 24 indexed citations

19.

Yu, Huan, Meng Ma, Junya Yan, et al.. (2017). Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. Journal of Translational Medicine. 15(1). 243–243. 19 indexed citations

20.

Yu, Jiayi, Xiaowen Wu, Huan Yu, et al.. (2017). Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. Translational Oncology. 10(5). 719–725. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact